Consensus $7.53. Sees FY25 revenue up 10%-12%, consensus $209.78B. Sees FY25 capital expenditures $500M-$550M. Sees FY25 adjusted free cash flow $1B. Sees FY25 effective tax rate 23%-25%. The company said, “The company raised its fiscal year 2025 outlook for non-GAAP diluted EPS to $7.55 to $7.70 from the preliminary outlook of at least $7.50 previously communicated during the company’s third quarter fiscal year 2024 earnings release. The company updated its Pharmaceutical and Specialty Solutions segment profit growth outlook to 1% to 3% growth, from at least 1% growth. The company also improved its fiscal year 2025 outlooks for Interest and other, diluted weighted average shares outstanding and share repurchases.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health Reports Fourth Quarter and Fiscal Year 2024 Results and Raises Fiscal Year 2025 Guidance
- Options Volatility and Implied Earnings Moves This Week, August 12 – August 15, 2024
- CAH Earnings this Week: How Will it Perform?
- Cardinal Health price target lowered to $107 from $115 at Citi
- Cardinal Health added to ‘Tactical Outperform’ list at Evercore ISI